1024 related articles for article (PubMed ID: 11889194)
1. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
4. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
7. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
Ryan AS; Egan JM; Habener JF; Elahi D
J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
[TBL] [Abstract][Full Text] [Related]
8. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Degn KB; Brock B; Juhl CB; Djurhuus CB; Grubert J; Kim D; Han J; Taylor K; Fineman M; Schmitz O
Diabetes; 2004 Sep; 53(9):2397-403. PubMed ID: 15331551
[TBL] [Abstract][Full Text] [Related]
11. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
13. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
14. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.
Banarer S; McGregor VP; Cryer PE
Diabetes; 2002 Apr; 51(4):958-65. PubMed ID: 11916913
[TBL] [Abstract][Full Text] [Related]
15. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
16. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
18. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
19. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
[TBL] [Abstract][Full Text] [Related]
20. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]